LiGalli

What LiGalli does

LiGalli B.V. is a privately held Dutch medical device company founded in 2014 (with platform development initiated in 2016) and headquartered at the Leiden Bio Science Park. The company develops the MedRing, a self-insertable, programmable vaginal drug delivery device designed to be worn for up to 28 days, releasing precise, scheduled doses of medication via the vaginal wall — a route that bypasses hepatic first-pass metabolism and is intended to enable lower dosing with fewer side effects than oral alternatives. The current lead clinical program targets overactive bladder (OAB) using intravaginal oxybutynin, with first-in-human and 28-day tolerability studies demonstrating favorable pharmacokinetics and patient acceptability.

The company's platform integrates three components: the MedRing hardware device, a Bluetooth-connected Companion App (iOS/Android) for personalized scheduling and monitoring within clinician-defined safety boundaries, and a GDPR-compliant Cloud Data Platform for treatment data storage and sharing with healthcare professionals. The system also monitors bio signals (including temperature for compliance) and is architected to support advanced features such as titration, tapering, chronotherapy, and potential closed-loop dosing. Core intellectual property is protected by basic patents granted in the EU, US, China, and Japan.

LiGalli operates a B2B2C commercial model targeting healthcare providers (gynecologists, urologists, general practitioners) and healthcare systems, with the MedRing prescribed and distributed through medical channels to women with chronic conditions. Revenue is expected to derive from hardware device sales, subscription/companion app services, and data platform services — though the company is pre-commercial, with products not yet on market. Go-to-market readiness is supported by an extensive development and clinical partnership network including Demcon (product development and investor), Ardena (pharmaceutical development), S3 Connected Health (digital health platform), CHDR (clinical research), and multiple academic medical centers (Haaglanden MC, Maxima MC, University of Twente, University of Antwerp, Queens University Belfast). The company has raised approximately €12.6 million across a Series A (June 2020, €6M, led by Demcon) and Series B (January 2022, €6.6M), plus a Dutch government MIT subsidy.

Name

LiGalli

Legal name

LiGalli B.V.

Website

https://ligalli.health

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

LiGalli B.V. is a Dutch medical device company developing the MedRing, a programmable vaginal drug delivery platform with companion app and cloud data infrastructure, targeting women with chronic conditions such as overactive bladder via healthcare-provider-prescribed B2B2C channels; the company is pre-commercial and currently advancing clinical trials.

Ownership category

akta.pro rank

Product category

Women's Health Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)

Keywords

• Vaginal drug delivery
• Women's health devices
• Intelligent drug delivery
• Medical device platform
• Digital health monitoring

Headquarters

HQ city

Leiden

HQ country

Netherlands

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. MedRing Device Sales: Sale of the MedRing intelligent drug delivery device, a programmable vaginal ring for personalized medication delivery lasting up to 28 days.
2. Companion App Subscription: Digital platform services through the Companion App enabling patients to schedule and monitor drug administration, with account administration and data storage capabilities.
3. Cloud Data Platform Services: Secure data storage and management services for treatment data, enabling sharing with healthcare professionals. GDPR-compliant data handling for pharmaceutical and medical device industry research.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

LiGalli develops and manufactures the MedRing, a self-insertable vaginal medical device designed to deliver programmable, personalized doses of medication for up to 28 days while monitoring bio signals. The offering is a three-part platform consisting of the MedRing hardware device, a Bluetooth-connected Companion App (iOS & Android) for scheduling and monitoring, and a Cloud Data Platform for secure storage and sharing of treatment data with healthcare professionals.

Product overview

LiGalli offers the MedRing Platform, a comprehensive intelligent drug delivery and monitoring solution for women's health. The platform consists of three integrated components: (1) the MedRing device — a self-insertable vaginal ring that delivers precise drug doses over 28 days and monitors bio signals; (2) the Companion App — a smartphone application (iOS & Android) connected via Bluetooth for personalized scheduling and treatment monitoring; and (3) the Data Platform (Cloud) — secure cloud infrastructure for data storage and healthcare professional sharing. The platform represents a second-generation vaginal ring with smart technology, programmable drug delivery schedules, and continuous monitoring capabilities.

Differentiator

Problem solved

Functional benefit

Brands

• MedRing: The LiGalli MedRing is a self-insertable and removable medical device designed to be placed into the vagina up to 28 days to release precise doses of medication according to a personalized delivery schedule. It is the first personalized vaginal drug delivery device.

Products and services

• MedRing A self-insertable and removable vaginal medical device placed into the vagina for up to 28 days to release precise doses of medication according to a personalized delivery schedule. Includes bio signal monitoring and Bluetooth connectivity.
• Companion App A smartphone application (iOS & Android) that connects to the MedRing via Bluetooth, enabling patients to schedule and monitor drug administration within predefined boundaries and track treatment progress.
• Cloud Data Platform A cloud environment that receives data from the Companion App to back-up personal settings, device configuration and treatment data, enabling secure storage and sharing of health data with healthcare professionals with patient consent.

Quantifiable outcome

• First-in-human study demonstrated favorable vaginal absorption and pharmacokinetics for oxybutynin administration via MedRing
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• DemconcoreTechnology or Integration · 1 January 2020Development partner providing product development expertise. Demcon is a technology company with deep involvement in LiGalli's MedRing development from early stages. Demcon Investment also provided funding support.
• S3 Connected HealthcoreTechnology or Integration · 1 January 2020Development partner contributing connected health and digital health platform expertise to LiGalli's cloud infrastructure and data platform development.
• ArdenacoreStrategic or Co-development Partner · 1 January 2020Development partner providing pharmaceutical development expertise for the MedRing drug delivery platform.
• CHDR (Centre for Human Drug Research)coreStrategic or Co-development Partner · 1 January 2020Clinical research organization conducting LiGalli's first-in-human study and subsequent clinical trials including the oxybutynin MedRing OAB studies.
• Haaglanden Medical CentercoreStrategic or Co-development Partner · 1 January 2020Medical center partner contributing clinical expertise and conducting clinical studies for the MedRing platform.
• Maxima Medical CentercoreStrategic or Co-development Partner · 1 January 2020Medical center partner contributing to clinical research and development of the MedRing platform for women's health applications.
• University of TwentecoreStrategic or Co-development Partner · 1 January 2020Academic partner contributing research expertise in medical device development and women's health technology.
• Roland BergerminorImplementation/ SI/ Consulting Partner · 1 January 2020Strategic consulting partner providing advisory services for business strategy and market development in the medical devices sector.
• Queens University BelfastminorStrategic or Co-development Partner · 1 January 2020Academic research partner contributing to development and scientific validation of the MedRing platform.
• University of AntwerpminorStrategic or Co-development Partner · 1 January 2020Academic partner contributing research expertise in women's health and pharmaceutical development.
• Gimix (TwentyNext)minorStrategic or Co-development Partner · 1 January 2019Partner resulting from MIT subsidy award, providing additional development support and expertise. Gimix rebranded as TwentyNext in July 2022.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Bayer (Women's Health / Pharma): Markets NuvaRing, one of the most established vaginal contraceptive rings, and has broad women's health and contraceptive franchises. Comparable to LiGalli as a large incumbent operating in the vaginal drug delivery space.
• Organon & Co. Global women's health spinoff from Merck with a broad portfolio including contraceptive vaginal rings (e.g., NuvaRing). Comparable to LiGalli as a large incumbent in the same women's health drug delivery category.
• TherapeuticsMD (now part of Mayne Pharma): Women's health specialty company (acquired by Mayne Pharma) that developed hormone therapies including vaginal inserts. Comparable to LiGalli given its women's health focus and vaginal drug delivery experience.
• Insulet Corporation: Markets the Omnipod tubeless insulin pump, a connected, wearable drug delivery device paired with a smartphone app and cloud data. Comparable to LiGalli in pioneering connected, app-controlled drug delivery platforms with biometric monitoring.
• Tandem Diabetes Care: Developer of connected insulin pumps with smartphone control and cloud data sharing. Comparable to LiGalli in combining a wearable drug delivery device with a digital companion app and cloud data platform for therapy management.

Direct peers

• Mithra Pharmaceuticals: Belgian women's health company that developed and commercialized Estelle, a combined oral contraceptive, and has historically worked on vaginal ring drug delivery. Highly comparable to LiGalli as a women's health-focused firm developing vaginal drug delivery platforms in Europe.
• Evofem Biosciences: Women's health company behind Phexxi, a vaginal pH modulator for contraception and STI prevention. Closely comparable to LiGalli given its focus on vaginal-route women's health products and similar commercial-stage profile.
• Population Council: Nonprofit developer of long-acting vaginal rings for contraception and HIV prevention (e.g., dapivirine ring). Comparable to LiGalli as a developer of programmable, sustained-release vaginal drug delivery platforms for women's health.

Emerging players

• Dare Bioscience: US clinical-stage women's health company advancing novel therapies including vaginal and hormone-based products. Comparable to LiGalli as a smaller, indication-focused women's health drug delivery developer targeting underserved conditions.
• Agile Therapeutics: Women's health company developing Twirla, a transdermal contraceptive patch, focused on novel hormone delivery for women. Comparable to LiGalli as a smaller player working on alternative delivery formats in women's health.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/medring-by-ligalli

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LiGalli